Adirondack Research & Management’s Trinity Biotech TRIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-2,354
Closed -$365K 96
2019
Q4
$365K Sell
2,354
-417
-15% -$59.5K 0.32% 70
2019
Q3
$503K Sell
2,771
-727
-21% -$189K 0.44% 63
2019
Q2
$866K Sell
3,498
-185
-5% -$66K 0.62% 49
2019
Q1
$1.57M Sell
3,683
-111
-3% -$45.8K 0.98% 37
2018
Q4
$1.3M Buy
3,794
+59
+2% +$27.3K 0.81% 44
2018
Q3
$2.24M Buy
3,735
+315
+9% +$205K 0.84% 51
2018
Q2
$2.56M Buy
3,420
+698
+26% +$504K 1% 43
2018
Q1
$2.1M Hold
2,722
0.84% 48
2017
Q4
$2.08M Buy
2,722
+494
+22% +$382K 0.82% 51
2017
Q3
$1.88M Buy
2,228
+88
+4% +$73.6K 0.73% 50
2017
Q2
$1.93M Hold
2,140
0.75% 52
2017
Q1
$1.91M Buy
2,140
+306
+17% +$287K 0.69% 54
2016
Q4
$1.9M Sell
1,834
-935
-34% -$966K 0.65% 56
2016
Q3
$5.49M Hold
2,769
1.98% 17
2016
Q2
$4.71M Hold
2,769
1.77% 17
2016
Q1
$4.84M Buy
2,769
+36
+1% +$57.3K 1.76% 16
2015
Q4
$4.82M Buy
2,733
+718
+36% +$1.27M 1.74% 21
2015
Q3
$3.46M Buy
2,015
+55
+3% +$133K 1.33% 37
2015
Q2
$5.31M Buy
1,960
+446
+29% +$1.16M 1.95% 16
2015
Q1
$4.37M Sell
1,514
-133
-8% -$369K 1.69% 25
2014
Q4
$4.33M Buy
1,647
+176
+12% +$455K 1.62% 21
2014
Q3
$4.03M Buy
1,471
+240
+19% +$780K 1.5% 27
2014
Q2
$4.25M Buy
1,231
+154
+14% +$548K 1.44% 30
2014
Q1
$3.91M Hold
1,077
1.5% 27
2013
Q4
$4.06M Hold
1,077
1.97% 9
2013
Q3
$3.51M Hold
1,077
2.02% 5
2013
Q2
$2.72M Buy
+1,077
New +$2.68M 2.03% 5

Other funds holding TRIB

Adirondack Research & Management's TRIB Position: Q1 2020 in Review

Adirondack Research & Management sold out of Trinity Biotech (TRIB) in Q1 2020, closing a stake of 2,354 shares — an estimated $365K sold.

Adirondack Research & Management first reported a position in TRIB in Q2 2013 and held it in 27 quarters. The position peaked at $5.49M in Q3 2016. 22 funds tracked by Wall St. Rank hold TRIB as of Q1 2020.

  • Adirondack Research & Management reported no remaining Trinity Biotech position as of Q1 2020 after selling out during the quarter.
  • Adirondack Research & Management sold 2,354 Trinity Biotech shares in Q1 2020, an estimated $365K.
  • Adirondack Research & Management first reported a position in Trinity Biotech in Q2 2013 and held it in 27 quarters.
  • Adirondack Research & Management's Trinity Biotech position peaked at $5.49M in Q3 2016.
  • 22 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2020.

Based on Adirondack Research & Management's 13F filing for Q1 2020, filed 13 May 2020.